Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 51

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 51
---
 also disclosed in the application, but the data in the application is primarily concerned with IO104.1, as such prosecution is focused on securing claims to this compound.

•IO112 (Arginase 1): We own three patent families covering compositions of matter related to IO112, which were filed between 2017 through 2023. These are Family 15 as listed above, plus Families 6 and 7 set out below. 

•Family 6 is based on a PCT application filed October 6, 2017. Patents granted from this family will expire October 6, 2037 based on a normal 20 year term. In the United States, there is a granted patent expiring October 6, 2037 (no patent term adjustment) which covers IO112 as a composition of matter and methods of treatment using IO112. A separate granted patent in the United States expiring October 6, 2037 (a patent term adjustment of 341 days was awarded but the term was reduced due to the filing of a terminal disclaimer) covers methods of preparing a pharmaceutical composition comprising IO112 . Granted patents in Australia, Europe, Israel, Japan, Republic of Korea, Mexico and Singapore cover IO112 as a composition of matter, as well as nucleotides encoding IO112 and methods of treatment using the same. The family also includes pending applications in Europe, the United States, Hong Kong, China, and Canada. This family is also relevant to Arginase 2 and the granted patents in Australia, Europe, Israel and Mexico also cover peptides from the corresponding immunogenic hotspot in Arginase 2; and  

43

•Family 7 is based on a PCT application filed September 24, 2019. Patents granted from this family will expire September 24, 2039 based on a normal 20 year term. In the United States, there is a granted patent covering IO112 as a composition of matter and methods of treatment using IO112, which will expire on July 23, 2041 due to 668 days patent term adjustment. The family also includes pending applications in the United States, Europe, Australia, Canada, Israel, Republic of Korea, Mexico, and Singapore. The claims are directed specifically to IO112, and uses thereof. Grant is underway in China and Japan. 

•We have additional patent families relevant to the following targets: 

•TDO: We own one patent family based on a PCT application filed September 15, 201